Vipadenant, also known as BIIB014, CEB-4520, is a potent, selective and orally available adenosine A2A receptor antagonist under development for for Parkinson's disease. Vipadenant demonstrates strong oral activity in commonly used models of Parkinson's disease. Vipadenant has shown excellent preclinical pharmacokinetics and has successfully completed phase I clinical studies.
臺(tái)州市科瑞生物技術(shù)有限公司
聯(lián)系商家時(shí)請(qǐng)?zhí)峒癱hemicalbook,有助于交易順利完成!
crene